These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 32297584)
1. Recent Studies on Design and Development of Drugs Against Alzheimer's Disease (AD) Based on Inhibition of BACE-1 and Other AD-causative Agents. Gupta SP; Patil VM Curr Top Med Chem; 2020; 20(13):1195-1213. PubMed ID: 32297584 [TBL] [Abstract][Full Text] [Related]
2. New neurogenic lipoic-based hybrids as innovative Alzheimer's drugs with σ-1 agonism and β-secretase inhibition. Estrada M; Pérez C; Soriano E; Laurini E; Romano M; Pricl S; Morales-García JA; Pérez-Castillo A; Rodríguez-Franco MI Future Med Chem; 2016 Jul; 8(11):1191-207. PubMed ID: 27402296 [TBL] [Abstract][Full Text] [Related]
3. From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Protein-Templated Synthesis. Nozal V; García-Rubia A; Cuevas EP; Pérez C; Tosat-Bitrián C; Bartolomé F; Carro E; Ramírez D; Palomo V; Martínez A Angew Chem Int Ed Engl; 2021 Aug; 60(35):19344-19354. PubMed ID: 34169618 [TBL] [Abstract][Full Text] [Related]
4. Semi-synthetic isoflavones as BACE-1 inhibitors against Alzheimer's disease. Ribaudo G; Coghi P; Zanforlin E; Law BYK; Wu YYJ; Han Y; Qiu AC; Qu YQ; Zagotto G; Wong VKW Bioorg Chem; 2019 Jun; 87():474-483. PubMed ID: 30927588 [TBL] [Abstract][Full Text] [Related]
5. Development and Structural Modification of BACE1 Inhibitors. Gu T; Wu WY; Dong ZX; Yu SP; Sun Y; Zhong Y; Lu YT; Li NG Molecules; 2016 Dec; 22(1):. PubMed ID: 28025519 [TBL] [Abstract][Full Text] [Related]
6. Novel small molecule therapeutic agents for Alzheimer disease: Focusing on BACE1 and multi-target directed ligands. Iraji A; Khoshneviszadeh M; Firuzi O; Khoshneviszadeh M; Edraki N Bioorg Chem; 2020 Apr; 97():103649. PubMed ID: 32101780 [TBL] [Abstract][Full Text] [Related]
7. Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR). Ferreira JPS; Albuquerque HMT; Cardoso SM; Silva AMS; Silva VLM Eur J Med Chem; 2021 Oct; 221():113492. PubMed ID: 33984802 [TBL] [Abstract][Full Text] [Related]
8. Multifunctional iminochromene-2H-carboxamide derivatives containing different aminomethylene triazole with BACE1 inhibitory, neuroprotective and metal chelating properties targeting Alzheimer's disease. Iraji A; Firuzi O; Khoshneviszadeh M; Tavakkoli M; Mahdavi M; Nadri H; Edraki N; Miri R Eur J Med Chem; 2017 Dec; 141():690-702. PubMed ID: 29107423 [TBL] [Abstract][Full Text] [Related]
9. BACE inhibitors as potential therapeutics for Alzheimer's disease. Evin G; Kenche VB Recent Pat CNS Drug Discov; 2007 Nov; 2(3):188-99. PubMed ID: 18221231 [TBL] [Abstract][Full Text] [Related]
10. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease. Moussa CE Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of BACE1 for therapeutic use in Alzheimer's disease. Luo X; Yan R Int J Clin Exp Pathol; 2010 Jul; 3(6):618-28. PubMed ID: 20661410 [TBL] [Abstract][Full Text] [Related]
12. The Structure and Function of α, β and γ-Secretase as Therapeutic Target Enzymes in the Development of Alzheimer's Disease: A Review. Ahmad SS; Khan S; Kamal MA; Wasi U CNS Neurol Disord Drug Targets; 2019; 18(9):657-667. PubMed ID: 31608840 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of quinazolinone-based hydrazones with potential use in Alzheimer's disease. Haghighijoo Z; Firuzi O; Hemmateenejad B; Emami S; Edraki N; Miri R Bioorg Chem; 2017 Oct; 74():126-133. PubMed ID: 28780149 [TBL] [Abstract][Full Text] [Related]
14. Guanidine-based β amyloid precursor protein cleavage enzyme 1 (BACE-1) inhibitors for the Alzheimer's disease (AD): A review. Gehlot P; Kumar S; Kumar Vyas V; Singh Choudhary B; Sharma M; Malik R Bioorg Med Chem; 2022 Nov; 74():117047. PubMed ID: 36265268 [TBL] [Abstract][Full Text] [Related]
15. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133 [TBL] [Abstract][Full Text] [Related]
16. In-silico Studies and Biological Activity of Potential BACE-1 Inhibitors. Arya R; Paliwal S; Gupta SP; Sharma S; Madan K; Mishra A; Verma K; Chauhan N Comb Chem High Throughput Screen; 2021; 24(5):729-736. PubMed ID: 32957879 [TBL] [Abstract][Full Text] [Related]
17. BACE1 in Alzheimer's disease. Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063 [TBL] [Abstract][Full Text] [Related]
19. BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants. Timmers M; Barão S; Van Broeck B; Tesseur I; Slemmon J; De Waepenaert K; Bogert J; Shaw LM; Engelborghs S; Moechars D; Mercken M; Van Nueten L; Tritsmans L; de Strooper B; Streffer JR J Alzheimers Dis; 2017; 56(4):1437-1449. PubMed ID: 28157093 [TBL] [Abstract][Full Text] [Related]
20. Beta-secretase (BACE) as a drug target for Alzheimer's disease. Vassar R Adv Drug Deliv Rev; 2002 Dec; 54(12):1589-602. PubMed ID: 12453676 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]